TransMedics Group (TMDX) Stock Price, News & Analysis

Company Overview

TransMedics Group, Inc. is a medical technology company focused on improving organ transplantation. The company develops and commercializes organ preservation and transport technologies designed to maintain donor organs in a functioning condition outside the body, potentially supporting evaluation and extending the time available for transplantation.

Its primary product is the Organ Care System (OCS), a portable perfusion platform that circulates oxygenated, nutrient-enriched fluid through donor organs. TransMedics offers OCS technologies for heart, lung and liver transplantation. The company also provides the National OCS Program, which combines its technology with organ retrieval, transportation, perfusion and clinical support services for transplant centers.

TransMedics serves hospitals, transplant centers and organ procurement organizations in the United States and select international markets. The company is headquartered in Andover, Massachusetts, and was founded by Waleed Hassanein, who serves as its president and chief executive officer.

Key Stats

• Today's Range: $86.50 to $89.80
• 50-Day Range: $71.13 to $94.77
• 52-Week Range: $60.10 to $156.00
• Volume: 743,533 shs
• Average Volume: 1.03 million shs
• Market Capitalization: $3.04 billion
• P/E Ratio: 22.64
• Dividend Yield: N/A
• Price Target: $121.10
• Consensus Rating: Hold

TransMedics Group Stock Analysis - MarketRank™

TransMedics Group scored higher than 90% of companies evaluated by MarketBeat, and ranked 24th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

TransMedics Group has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 5 buy ratings, 6 hold ratings, and 1 sell rating.

Upside Potential

TransMedics Group has a consensus price target of $121.10, representing about 37.2% upside from its current price of $88.28.

Amount of Analyst Coverage

TransMedics Group has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 54.79%

Earnings Growth

Earnings for TransMedics Group are expected to grow by 54.79% in the coming year, from $1.46 to $2.26 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of TransMedics Group is 22.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.12.

Price to Earnings Ratio vs. Sector

The P/E ratio of TransMedics Group is 22.74, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.41.

Price to Earnings Growth Ratio

TransMedics Group has a PEG Ratio of 1.19. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

TransMedics Group has a P/B Ratio of 6.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

25.11% of the float of TransMedics Group has been sold short.

Short Interest Ratio / Days to Cover

TransMedics Group has a short interest ratio ("days to cover") of 12.78, which indicates bearish sentiment.

Change versus previous month

Short interest in TransMedics Group has recently increased by 2.13%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TransMedics Group does not currently pay a dividend.

Dividend Growth

TransMedics Group does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.73

News Sentiment

TransMedics Group has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for TransMedics Group this week, compared to 5 articles on an average week.

Search Interest

12 people have searched for TMDX on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.

MarketBeat Follows

7 people have added TransMedics Group to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.

Company Ownership

• Score: 3.1 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $109,058.00 in company stock, which represents 0.0036% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, TransMedics Group insiders have bought more of their company's stock than they have sold. Specifically, they have bought $109,058.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

6.90% of the stock of TransMedics Group is held by insiders.

Percentage Held by Institutions

99.67% of the stock of TransMedics Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 9/22/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:TMDX
• CIK: 1756262
• Web: www.transmedics.com
• Phone: (978) 552-0900
• Fax: N/A
• Employees: 898
• Year Founded: 1998

Price Target and Rating

• Average Price Target for TransMedics Group: $121.10
• High Price Target: $175.00
• Low Price Target: $77.00
• Potential Upside/Downside: +37.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.89
• Trailing P/E Ratio: 22.64
• Forward P/E Ratio: 60.32
• P/E Growth: 1.19
• Net Income: $190.29 million
• Net Margins: 22.69%
• Pretax Margin: 10.85%
• Return on Equity: 15.88%
• Return on Assets: 5.95%

Debt

• Debt-to-Equity Ratio: 1.62
• Current Ratio: 6.62
• Quick Ratio: 6.07

Sales & Book Value

• Annual Sales: $605.49 million
• Price / Sales: 5.03
• Cash Flow: $4.00 per share
• Price / Cash Flow: 22.01
• Book Value: $13.79 per share
• Price / Book: 6.39

Miscellaneous

• Outstanding Shares: 34,560,000
• Free Float: 32,176,000
• Market Cap: $3.04 billion
• Optionable: Optionable
• Beta: 1.90